Parthasarathi Balasamudram Chandrasekhar, Kumar Binod, Nagar Gaurav, Manjunathachar Haranahally Vasanthachar, de la Fuente José, Ghosh Srikant
Entomology Laboratory, Division of Parasitology, ICAR-Indian Veterinary Research Institute, Izatnagar 243122, India.
Department of Veterinary Parasitology, College of Veterinary Science and AH, Junagadh Agricultural University, Junagadh 362001, India.
Vaccines (Basel). 2021 Feb 26;9(3):194. doi: 10.3390/vaccines9030194.
The control of cattle tick, is focused on repeated use of acaricides. However, due to growing acaricide resistance and residues problem, immunization of animals along with limited use of effective acaricides is considered a suitable option for the control of tick infestations. To date, more than fifty vaccine candidates have been identified and tested worldwide, but two vaccines were developed using the extensively studied candidate, . The main reason for limited vaccine commercialization in other countries is genetic diversity in the gene leading to considerable variation in vaccine efficacy. India, with 193.46 million cattle population distributed in 28 states and 9 union territories, is suffering from multiple tick infestation dominated by . As has developed multi-acaricide resistance, an efficacious vaccine may provide a sustainable intervention for tick control. Preliminary experiments revealed that the presently available commercial vaccine based on the gene is not efficacious against Indian strain. In concert with the principle of reverse vaccinology, genetic polymorphism of the gene within Indian isolates of was studied. A 578 bp conserved nucleotide sequences of from 65 isolates collected from 9 Indian states was sequenced and revealed 95.6-99.8% and 93.2-99.5% identity in nucleotides and amino acids sequences, respectively. The identities of nucleotides and deduced amino acids were 94.7-99.8% and 91.8-99.5%, respectively, between full-length sequence (orf) of the gene of IVRI-I strain and published sequences of vaccine strains. Six nucleotides deletion were observed in Indian sequences. Four B-cell epitopes (D519-K554, H563-Q587, C598-T606, T609-K623), which are present in the conserved region of the IVRI-I sequence, were selected. The results confirm that the use of available commercial vaccines is not a suitable option against Indian isolates of . A country-specific multi-epitope vaccine consisting of four specific B-cell epitopes along with candidate molecules, subolesin and tropomyosin in chimeric/co-immunization format may provide a sustainable option for implementation in an integrated tick management system.
牛蜱的控制主要集中在反复使用杀螨剂上。然而,由于杀螨剂耐药性的不断增加和残留问题,对动物进行免疫接种并有限使用有效的杀螨剂被认为是控制蜱虫侵扰的合适选择。迄今为止,全球已鉴定并测试了五十多种候选疫苗,但有两种疫苗是使用经过广泛研究的候选疫苗开发的。其他国家疫苗商业化受限的主要原因是该基因的遗传多样性导致疫苗效力存在相当大的差异。印度拥有1.9346亿头牛,分布在28个邦和9个联邦属地,正遭受以[蜱虫种类未明确]为主的多种蜱虫侵扰。由于[蜱虫种类未明确]已产生多重杀螨剂耐药性,一种有效的疫苗可能为蜱虫控制提供可持续的干预措施。初步实验表明,目前基于该基因的商业疫苗对印度菌株无效。根据反向疫苗学原理,研究了印度[蜱虫种类未明确]分离株中该基因的遗传多态性。对从印度9个邦收集的65株[蜱虫种类未明确]分离株的578 bp保守核苷酸序列进行了测序,结果显示核苷酸序列和氨基酸序列的同一性分别为95.6 - 99.8%和93.2 - 99.5%。IVRI - I株该基因的全长序列(开放阅读框)与疫苗株的已发表序列之间,核苷酸和推导氨基酸的同一性分别为94.7 - 99.8%和91.8 - 99.5%。在印度[蜱虫种类未明确]序列中观察到六个核苷酸缺失。选择了存在于IVRI - I[蜱虫种类未明确]序列保守区域的四个B细胞表位(D519 - K554、H563 - Q587、C598 - T606、T609 - K623)。结果证实,使用现有的商业[蜱虫种类未明确]疫苗对印度[蜱虫种类未明确]分离株不是一个合适的选择。一种由四个特定B细胞表位以及候选分子亚油酸异构酶和原肌球蛋白组成的国家特异性多表位[蜱虫种类未明确]疫苗,以嵌合/联合免疫形式,可能为综合蜱虫管理系统的实施提供一个可持续的选择。